Quick Takeaways
- This page summarizes Eric Dobmeier's Form 4 filing for Structure Therapeutics Inc. (GPCR).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 25 Jun 2025, 17:45.
Eric Dobmeier - 23 Jun 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)
- Role
- Director
- Signature
- /s/ Jun Yoon, Attorney-in-Fact
- Issuer symbol
- GPCR
- Transactions as of
- 23 Jun 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 25 Jun 2025, 17:45:09 UTC
- Previous filing
- 13 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Eric Dobmeier filed Form 4 for Structure Therapeutics Inc. (GPCR) on 25 Jun 2025."
What Changed
- Previous filing in this sequence was filed on 13 Jun 2025.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001202785
Primary reporting owner
DOBMEIER ERIC
- Relationship
- Director
- Address
- C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO
- Signature
- /s/ Jun Yoon, Attorney-in-Fact
- Signature date
- 25 Jun 2025
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
GPCR
transaction
Derivative
Share Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +51,804
- Change %
- Price
- $0.000000
- Shares after
- 51,804
- Date
- 23 Jun 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 51,804
- Exercise price
- $7.37
- Footnotes
- F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). |
| F2 | The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, |
| F3 | The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |